At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 182 enrolled
Drug / intervention
risankizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II/III, Randomized, Double-blind Study to Evaluate Efficacy and Safety of Two Different Dose Regimens of BI 655066 (Risankizumab) and Placebo and Maintenance of Response of BI 655066 (Risankizumab) Administered Subcutaneously in Japanese Patients With Moderate to Severe Chronic Plaque Type Psoriasis.
In Brief
A Phase 2 clinical trial evaluating risankizumab and placebo for risankizumab for Psoriasis. Completed, enrolled 182 participants.
Detailed Summary
This is a randomized double blind, double dummy, placebo controlled, parallel design study that is being performed to assess the safety and efficacy of BI 655066 (risankizumab).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsBoehringer Ingelheim
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartDec 2016
First PostedDec 2016
Primary CompletionSep 2017
Study CompletionJun 2018
TodayJul 2026
First PostedDec 21, 2016
Enrollment StartDec 2, 2016
Primary CompletionSep 21, 2017
Study CompletionJun 20, 2018
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.5 years ago
Interventions
risankizumabdrug
Risankizumab pre-filled syringe, administered by subcutaneous (SC) injection
placebo for risankizumabdrug
Placebo for risankizumab pre-filled syringe, administered by subcutaneous (SC) injection